Intensity Therapeutics Enters Securities Purchase Agreement

Intensity Therapeutics, Inc. ( (INTS) ) has provided an announcement.

On October 30, 2025, Intensity Therapeutics, Inc. entered into a Securities Purchase Agreement with an institutional investor to sell 5,000,000 shares of common stock at $0.80 per share, raising approximately $4 million. The offering is expected to close on or around November 3, 2025, and the proceeds will be used for clinical trials, working capital, and general corporate purposes. The company anticipates having sufficient cash until the end of the first quarter of 2027.

The most recent analyst rating on (INTS) stock is a Buy with a $1.50 price target. To see the full list of analyst forecasts on Intensity Therapeutics, Inc. stock, see the INTS Stock Forecast page.

Spark’s Take on INTS Stock

According to Spark, TipRanks’ AI Analyst, INTS is a Underperform.

Intensity Therapeutics faces significant challenges typical of a pre-revenue biotech firm, including negative financial metrics and bearish technical indicators. While recent corporate announcements about cancer treatment progress are promising, they do not outweigh the financial and technical difficulties. The overall score reflects these challenges, positioning the stock at the lower end of the scoring range.

To see Spark’s full report on INTS stock, click here.

More about Intensity Therapeutics, Inc.

Intensity Therapeutics, Inc. is a late-stage clinical biotechnology company focused on developing novel intratumoral cancer therapies. Their proprietary non-covalent conjugation technology aims to kill tumors and enhance immune system recognition of cancers. The company has completed several clinical studies and is working on advancing its INT230-6 drug through various phases of trials, targeting different types of cancers.

Average Trading Volume: 26,434,144

Technical Sentiment Signal: Sell

Current Market Cap: $64.75M

For a thorough assessment of INTS stock, go to TipRanks’ Stock Analysis page.